A5055079192- CAR-T cell therapy research
- Viral Infectious Diseases and Gene Expression in Insects
- Acute Lymphoblastic Leukemia research
- Childhood Cancer Survivors' Quality of Life
- Immunodeficiency and Autoimmune Disorders
- Biosimilars and Bioanalytical Methods
- Infant Nutrition and Health
- Respiratory viral infections research
- Hematopoietic Stem Cell Transplantation
- Family Support in Illness
- Pregnancy and preeclampsia studies
- Ethics and Legal Issues in Pediatric Healthcare
- Child Nutrition and Feeding Issues
- Neonatal Respiratory Health Research
- Immune Cell Function and Interaction
- Hemoglobinopathies and Related Disorders
- Viral gastroenteritis research and epidemiology
- Diabetes and associated disorders
- Biomedical and Engineering Education
- Nanowire Synthesis and Applications
- Cancer Research and Treatments
- Infant Development and Preterm Care
- Neurological Complications and Syndromes
- Pediatric health and respiratory diseases
- Acute Myeloid Leukemia Research
Center for Cancer and Blood Disorders
2020-2025
Johns Hopkins All Children's Hospital
2024-2025
Johns Hopkins University
2024-2025
Mayo Clinic in Florida
2023
Phoenix Children's Hospital
2020-2023
Mayo Clinic Hospital
2021-2023
University of Arizona
2022-2023
Mayo Clinic in Arizona
2022
Jacksonville University
2019
University of Florida
2019
Chimeric Antigen Receptor (CAR) T-cell therapies have emerged as an effective and potentially curative immunotherapy for patients with relapsed or refractory malignancies. Treatment CD19 CAR T-cells has shown unprecedented results in hematological malignancies, including heavily leukemia, lymphoma, myeloma cases. Despite these encouraging results, therapy faces limitations, the lack of long-term responses nearly 50-70% treated low efficacy solid tumors. Among other reasons, restrictions are...
Florida Pediatric Bone Marrow Transplant and Cell Therapy Consortium (FPBCC) was formed in 2018 by five pediatric transplant programs Florida. The key objectives of the consortium are to improve outcomes for children undergoing HSCT through collaboration among centers, data sharing, implementation best practices, QI projects, prospective clinical trials. first step that process analyze from all participating centers identify areas improvement. In this report, we describe effectiveness...
Sickle cell disease (SCD) is a chronic hematologic disorder which causes progressive cerebral arteriopathy beginning in childhood. As result, arterial ischemic stroke major cause of morbidity and mortality SCD, SCD leading childhood worldwide. Allogenic hematopoietic stem transplant (HSCT) may be curative for individuals with SCD. Long-term outcomes effects are currently being studied. In this report, we describe child who presented at 6 years age was found to have severe form large vessel...
Pediatric patients with acute myeloid leukemia (AML) who undergo allogeneic hematopoietic stem cell transplantation (HSCT) continue to have high rates of relapse. In 2018, Phoenix Children's Hospital started using post-HSCT maintenance therapy in AML attempt decrease the number relapses after HSCT. This consisted hypomethylating agent azacitidine (AZA; 6 cycles starting on day +60) and prophylactic donor lymphocyte infusion (DLI; 3 escalating doses beginning +120). We aimed compare 2-year...
e14516 Background: IEC are arguably the most promising therapy in oncology, and FDA approvals for CAR T cells a testament to their real potential. This has led great growth of clinical trials (CT), making evaluation associated data increasingly challenging. To facilitate this process, we performed systematic review ClinicalTrials.gov focused on therapies oncology. We an analysis CT forecast trends 2025. Methods: registries were retrieved from with search query. included registered between...
Background While racial disparities in the clinical outcomes of hematopoietic stem cell transplant (HSCT) patients have been explored, quality life (QoL) during readjustment phase after has yet to be investigated pediatric patients. The objective this study was examine role patient race QoL at least two years HSCT. Procedure We conducted a retrospective chart review under 21 age diagnosis that received an allogeneic our institution between January 2007 and December 2017. Patient assessed...
While racial disparities in the clinical outcomes of hematopoietic stem cell transplant (HSCT) patients have been explored, quality life (QoL) during re-adjustment phase after are yet to be investigated pediatric patients. The objective this study was examine role patient race QoL at least 2 years HSCT.We conducted a retrospective chart review under 21 age diagnosis who received an allogeneic our institution between January 2007 and December 2017. Patient assessed using Pediatric...
Abstract Purpose: The incidence of severe combined immunodeficiency (SCID) in the United States was reported as 1 58,000 live births. In Arizona, it anticipated that newborn screening would identify two to four cases SCID per year. This estimate did not consider ethnic nuances with higher percentages American Indian and Hispanic populations compared national percentages. true non T-cell lymphopenia have previously been Arizona. Methods: A retrospective chart review performed abnormal Newborn...